Diabetes
Alimera Sciences' Medidur Trial Exceeds 500 Patient Mark in Phase 3 Trial Enrollment
Published in Diabetes Week, May 7th, 2007
Alimera Sciences, a privately held ophthalmic pharmaceutical company, and global drug delivery company pSivida Limited (NASDAQ:PSDV)(NASDAQ:ASX:)(NASDAQ:PSD)(NASDAQ:Xetra:)(NASDAQ:PSI) announced that enrollment for their Phase 3 global clinical trial, the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study has exceeded 50 percent. FAME is a double masked, randomized, multi-center study that will follow approximately 900 patients in the U.S., Canada, Europe and India for 36 months. The trial is studying the safety and efficacy of the novel treatment currently referred to as Medidur for diabetic macular edema (DME).
Medidur, a tiny, injectable intravitreal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2007-05-07)
More Articles from Diabetes Week
- Diabetes
Study shows food preparation may play a bigger role in chronic disease than was previously thought - Obesity and Diabetes
Chronically ill prisoners can face great healthcare problems - Obesity and Diabetes
Depression may trigger diabetes in older adults - Obesity and Diabetes
Infant formula may help prevent obesity - Diabetes
Abbott Announces New Glucerna Cereal, Shakes and Snack Bars Designed to Spike Taste Buds, Not Blood Sugar for People with Diabetes - Diabetes
American College of Physicians and American College of Physicians Foundation Launch Tools to Improve Diabetes Care - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
